Molica Stefano
Department of Hematology & Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy.
Int J Hematol Oncol. 2020 Nov 20;9(4):IJH31. doi: 10.2217/ijh-2020-0010.
Venetoclax - a novel, orally bioavailable inhibitor of B-cell lymphoma-2 - has demonstrated substantial clinical activity in the treatment of chronic lymphocytic leukemia. Alone or in combination with other targeted agents, venetoclax results in high rate of durable responses and undetectable measurable residual disease. The peculiarity of venetoclax is that it allows for fixed durations of therapy of 12 months in the frontline and 24 months in the relapsed/refractory setting, with a favorable impact on compliance and pharmacoeconomics. This approach implies a change of therapeutic paradigm in chronic lymphocytic leukemia from continuous to time-fixed therapy. Nowadays, it remains challenging to identify patients suitable for the optimal approach. Clinical trials addressing the issue of continuous versus time-limited therapy are ongoing.
维奈克拉——一种新型的、口服生物可利用的B细胞淋巴瘤-2抑制剂——已在慢性淋巴细胞白血病治疗中展现出显著的临床活性。单独使用或与其他靶向药物联合使用时，维奈克拉可带来高持久缓解率及不可检测的微小残留病。维奈克拉的独特之处在于，它在前线治疗中允许固定疗程为12个月，在复发/难治性情况下为24个月，对依从性和药物经济学有积极影响。这种方法意味着慢性淋巴细胞白血病的治疗模式从持续治疗转变为固定疗程治疗。如今，识别适合最佳治疗方法的患者仍然具有挑战性。针对持续治疗与限时治疗问题的临床试验正在进行中。
